A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine

References

• Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32–51. doi:10.1111/j.1360-0443.2010.03140.x.
   PubMed Web of Science ®Google Scholar
• Buster MCA, Brussel G, Brink W. An increase in opiate mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction. 2002;97(8):993–1001.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality amoung clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009;105(1):9–15. doi:10.1016/j.drugalcdep.2009.05.021.
   PubMed Web of Science ®Google Scholar
• Strang J, McCambridge J, Best D, Bestwick T, Bearn J, Rees S, Gossop M. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. Br Med J. 2003;326:959–60.
   PubMed Web of Science ®Google Scholar
• Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M, Salamina G, et al. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction. 2007;102(12):1954–59. doi:10.1111/j.1360-0443.2007.02025.x.
   PubMed Web of Science ®Google Scholar
• Merrall ELC, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J, Hutchinson SJ, Bird SM. Meta-analysis of drug related deaths soon after release from prison. Addiction. 2010;105(9):1545–54. doi:10.1111/j.1360-0443.2010.02990.x.
   PubMed Web of Science ®Google Scholar
• Bird SM, Hutchinson SJ. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996–99. Addiction. 2003;98(2):185–90.
   PubMed Web of Science ®Google Scholar
• Gibson A, Degenhardt L Mortality related to naltrexone in the treatment of opioid dependence: a comparative analysis. Sydney: National Drug and Alcohol Research Centre; 2005. Report No.: 229 Contract No.: Technical Report No. 229.
   Google Scholar
• National Consensus Development Panel on Effective Medical Treatment of Opiate A. Effective medical treatment of opiate addiction. Jama, 1998;280(22):1936–43.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;8(3): CD002209.
   Google Scholar
• Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust. 1999;170(3):104–09.
   PubMed Web of Science ®Google Scholar
• Farid WO, Dunlop SA, Tait RJ, Hulse GK. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol. 2008;6:125–50. doi:10.2174/157015908784533842.
   PubMed Web of Science ®Google Scholar
• Stoller KB, Bigelow GE, Walsh SL, Strain EC. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl). 2001;154(3):230–42.
   PubMed Web of Science ®Google Scholar
• Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009;104(1–2):73–77. doi:10.1016/j.drugalcdep.2009.03.020.
   PubMed Web of Science ®Google Scholar
• Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. Jama. 2001;285(1):45. doi:10.1001/jama.285.1.39.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane database of systematic reviews. 2014;(2).
   Google Scholar
• Schifano F, Corkery J, Gilvarry E, Deluca P, Oyefeso A, Ghodse HA. Buprenorphine mortality, seizure and prescription dat in the UK, 1980-2002. Hum Psychopharmacol. 2005;20(5):343–48. doi:10.1002/hup.698.
   PubMed Web of Science ®Google Scholar
• Kelty E, Hulse G. Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use. Addiction. 2012;107(10):1817–24. doi:10.1111/j.1360-0443.2012.03910.x.
   PubMed Web of Science ®Google Scholar
• Ngo HTT, Arnold-Reed DE, Hansson RC, Tait RJ, Hulse GK. Blood naltrexone levels over time following naltrexone implant. Prog Neuro-Psychopharmacology Biol Psychiatry. 2008;32(1):23–28. doi:10.1016/j.pnpbp.2007.06.007.
   PubMed Web of Science ®Google Scholar
• Hulse GK, O’Neil G, Arnold-Reed DE. Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin sser. Int J Gynecol Obstet. 2004;85(2):170–71.
   PubMed Web of Science ®Google Scholar
• Reece AS. Favourable mortality profile of naltrexone implants for opiate addiction. J Addict Dis. 2010;29:30–50. doi:10.1080/10550880903435988.
   PubMed Web of Science ®Google Scholar
• Tait RJ, Ngo HTT, Hulse G. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat. 2008;35:116–24. doi:10.1016/j.jsat.2007.08.014.
   PubMed Web of Science ®Google Scholar
• Hickman M, Degenhardt L, Farrell M, Hall W. Commentary on Kelty & Hulse (2012): is the comparison of mortality between patients prescribed implanted or oral naltrexone an unbiased and unconfounded comparison? Addiction. 2012;107(10):1825–26. doi:10.1111/j.1360-0443.2012.03966.x.
   PubMed Web of Science ®Google Scholar
• Holman CD, Bass AJ, Rouse IL, Hobbs MS. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health. 1999;23(5):453–59.
   PubMed Web of Science ®Google Scholar
• Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009;66(10):1108–15. doi:10.1001/archgenpsychiatry.2009.130.
   PubMed Web of Science ®Google Scholar
• Hulse GK, Arnold-Reed DE, O’Neil G, Chan CT, Hansson R, O’Neil P. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol. 2004;9(1):59–65. doi:10.1080/13556210410001674103.
   PubMed Web of Science ®Google Scholar
• Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction. 2000;95:77–84.
   PubMed Web of Science ®Google Scholar
• Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross-registry study. Drug Alcohol Depend. 2008;94(1):151–57. doi:10.1016/j.drugalcdep.2007.11.003.
   PubMed Web of Science ®Google Scholar
• Jimenez-Treviño L, Saiz PA, García-Portilla MP, Díaz-Mesa EM, Sánchez-Lasheras F, Burón P, Casares MJ, et al. A 25-year follow-up of patients admitted to methadone treatment for the first time: mortality and gender differences. Addict Behav. 2011;36(12):1184–90. doi:10.1016/j.addbeh.2011.07.019.
   PubMed Web of Science ®Google Scholar
• Pettinati HM, O’Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol. 2006;26(6):610–25. doi:10.1097/01.jcp.0000245566.52401.20.
   PubMed Web of Science ®Google Scholar